14-day Premium Trial Subscription Try For FreeTry Free
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

3 Biotech Stocks That Could Double Soon

06:44am, Wednesday, 21'st Jul 2021
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Moving Average Crossover Alert: Allakos (ALLK)

06:46am, Monday, 07'th Jun 2021
Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duo

Bear Of The Day: Allakos (ALLK)

11:16am, Friday, 21'st May 2021
Bear Of The Day: Allakos (ALLK)

7 of the Best Pharma Stocks to Buy Now

10:37am, Tuesday, 11'th May 2021
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first o
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast
Allakos has a molecule targeting a largely undiagnosed market. If their prevalence study is any good, the potential for the therapy is huge.
With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disea
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mas
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and m
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE